Shots:
- Biomunex to receive up front, development, regulatory & sales milestones, equity investment along with royalties on sales of therapies
- Onward get the right to pursue development, manufacture & commercialize first-in-class bispecific Ab. The companies will jointly develop the Ab during the preclinical and early clinical program
- Biomunex is responsible for early preclinical development, while Onward will complete the IND-enabling studies, and will be responsible for GMP manufacture, clinical development, and commercialization
Click here to read full press release/ article | Ref: PRNewswire | Image: Onward
The post Onward Signs a Worldwide Exclusive License and Co-Development Agreement with Biomunex for Immuno-Oncology first appeared on PharmaShots.
